Cytokinetics Inc

Common Name

Cytokinetics

Country

United States

Sector

Healthcare

Industry

Biotechnology

Employees

498

Ticker

CYTK

Exchange

NASDAQ/NGS

Website

cytokinetics.com

Description

Cytokinetics, Incorporated is a biopharmaceutical company specializing in the discovery, development, and commercialization of innovative muscle activators and inhibitors. Its primary mission is to ad... Show more

Income Statement Balance Sheet Group Entities

Cytokinetics's Financial Statements Preview

Below are the financial statements of Cytokinetics, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Interested in getting early access to our real-time standardized financial datafeed?

Learn More

All figures in millions of USD	2024 as of 2024-12-31	2023 as of 2023-12-31
Assets	—	—
Current assets	—	—
Cash and cash equivalents	94.86^a	113.02^a
Short-term investments	981.16^a	501.8^a
Accounts receivable	16.65^a	1.28^a
Prepaid expenses and other current assets	15.28^a	11.94^a
Total current assets	1,107.94^a	628.05^a
Long-term investments	145.06^a	40.53^a
Property and equipment, net	65.82^a	68.75^a
Operating lease right-of-use assets	75.16^a	78.99^a
Other assets	7.71^a	8^a
Total assets	1,401.67^a	824.32^a
Liabilities and stockholders' deficit	—	—
Current liabilities	—	—
Accounts payable	20.37^a	21.51^a
Accrued liabilities	55.32^a	42.64^a
Short-term operating lease liabilities	18.98^a	17.89^a
Current portion of long-term debt	11.52^a	10.08^a
Derivative liabilities measured at fair value	11.3^a	0^a
Deferred revenue	52.37^a	0^a
Other current liabilities	9.81^a	10.56^a
Total current liabilities	179.67^a	102.68^a
Term loans, net	93.23^a	58.38^a
Convertible notes, net	552.37^a	548.99^a
Liabilities related to revenue participation right purchase agreements, net	462.19^a	379.98^a
Long-term operating lease liabilities	112.58^a	120.43^a
Liabilities related to RPI Transactions measured at fair value	137^a	0^a
Other non-current liabilities	0^a	0.19^a
Total liabilities	1,537.05^a	1,210.64^a
Stockholders' deficit	—	—
Preferred stock	0^a	0^a
Common stock	0.12^a	0.1^a
Additional paid-in capital	2,563.88^a	1,725.82^a
Accumulated other comprehensive income (loss)	2.4^a	-0.01^a
Accumulated deficit	-2,701.76^a	-2,112.24^a
Total stockholders' deficit	-135.37^a	-386.32^a
Total liabilities and stockholders' deficit	1,401.67^a	824.32^a

Download Data

Verified Sources Behind Cytokinetics’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Cytokinetics’s data sources below and access millions more through our Disclosure Search.

a. Cytokinetics's Annual Report 2024

Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

Tracenable is building real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?

Explore Peer Companies

Welcome Back to Tracenable

Sign in to your account

Cytokinetics Inc

Cytokinetics's Financial Statements Preview

Verified Sources Behind Cytokinetics’s Financial Fundamentals Data

Access Standardized Financial Statements within Minutes of Disclosure

Explore Peer Companies

Arcellx Inc

Kymera Therapeutics Inc

Blueprint Medicines Corp

Vaxcyte Inc

Denali Therapeutics Inc

Crinetics Pharmaceuticals Inc